Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03939026
Title Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)
Acronym ALPHA
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Allogene Therapeutics
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.